Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles

References

• Musso O, Beraza N. Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor. Gut. 2019;68(10):1728–1730.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Adhoute X, Penaranda G, et al. Sorafenib: experience and better manage-ment of side effects improve overall survival in hepatocellular carcinoma patients: a real-life retrospective analysis. Liver Cancer. 2019;8(6):457–467.
   PubMed Web of Science ®Google Scholar
• Pinyol R, Montal R, Bassaganyas L, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019;68(6):1065–1075.
   PubMed Web of Science ®Google Scholar
• Tang X, Chen L, Li A, et al. Anti-GPC3 antibody modified sorafenib loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv. 2018;25(1):1484–1494.
   PubMed Web of Science ®Google Scholar
• Dietrich P, Koch A, Fritz V, et al. Wild type kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut. 2018;67(7):1328–1341.
   PubMed Web of Science ®Google Scholar
• Personeni N, Pressiani T, Bozzarelli S, et al. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol. 2019;11(10):788–803.
   PubMed Web of Science ®Google Scholar
• Jeric I, Maurer G, Cavallo AL, et al. A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. Nat Commun. 2016;7:13781.
   PubMed Web of Science ®Google Scholar
• Kim MN, Lee SM, Kim JS, et al. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2019;84(4):809–817.
   PubMed Web of Science ®Google Scholar
• Li A, Zhang R, Zhang Y, et al. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway. Am J Transl Res. 2019;11(9):5573–5585.
   PubMed Web of Science ®Google Scholar
• Samarin J, Laketa V, Malz M, et al. PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. Hepatology. 2016;63(3):813–826.
   PubMed Web of Science ®Google Scholar
• Galuppo R, Maynard E, Shah M, et al. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPKand WNT/β-catenin pathways. Anticancer Res. 2014;34(4):1709–1713.
   PubMed Web of Science ®Google Scholar
• Saraswati S, Alhaider A, Abdelgadir AM, et al. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma. Cell Commun Signal. 2019;17(1):127.
   PubMed Web of Science ®Google Scholar
• Gedaly R, Angulo P, Chen C, et al. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res. 2012;32(7):2531–2536.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xie C, Li A, et al. PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway. Am J Transl Res. 2019;11(8):5134–5149.
   PubMed Web of Science ®Google Scholar
• Takaya H, Namisaki T, Shimozato N, et al. ADAMTS13 and von willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. World J Gastrointest Oncol. 2019;11(5):424–435.
   PubMed Web of Science ®Google Scholar
• Kahraman DC, Kahraman T, Cetin-Atalay R. Targeting PI3K/Akt/mTOR pathway identifies differential expression and functional role of IL8 in liver cancer stem cell enrichment. Mol Cancer Ther. 2019;18(11):2146–2157.
   PubMed Web of Science ®Google Scholar
• Ebrahim HM, El-Rouby MN, Morsy ME, et al. The synergistic cytotoxic effect of laser-irradiated gold nanoparticles and sorafenib against the growth of a human hepatocellular carcinoma cell line. Asian Pac J Cancer Prev. 2019;20(11):3369–3376.
   PubMedGoogle Scholar
• Gani SA, Muhammad SA, Kura AU, et al. Effect of protocatechuic acid-layered double hydroxide nanoparticles on diethylnitrosamine/phenobarbital-induced hepatocellular carcinoma in mice. PLoS One. 2019;14(5):e0217009.
   PubMed Web of Science ®Google Scholar
• Ballesteros CAS, Correa DS, Zucolotto V. Polycaprolactone nanofiber mats decorated with photoresponsive nanogels and silver nanoparticles: slow release for antibacterial control. Mater Sci Eng C Mater Biol Appl. 2020;107:110334.
   PubMed Web of Science ®Google Scholar
• Diyanat M, Saeidian H, Baziar S, et al. Preparation and characterization of polycaprolactone nanocapsules containing pretilachlor as a herbicide nanocarrier. Environ Sci Pollut Res Int. 2019;26(21):21579–21588.
   PubMed Web of Science ®Google Scholar
• Alkholief M, Albasit H, Alhowyan A, et al. Employing a PLGA-TPGS based nanoparticle to improve the ocular delivery of acyclovir. Saudi Pharm J. 2019;27(2):293–302.
   PubMed Web of Science ®Google Scholar
• Katiyar SS, Kushwah V, Dora CP, et al. Lipid and TPGS based novel core-shell type nanocapsular sustained release system of methotrexate for intravenous application. Colloids Surf B Biointerfaces. 2019;174:501–510.
   PubMed Web of Science ®Google Scholar
• Chauhan DS, Bukhari AB, Ravichandran G, et al. Enhanced EPR directed and imaging guided photothermal therapy using vitamin E modified toco-photoxil. Sci Rep. 2018;8(1):16673.
   PubMed Web of Science ®Google Scholar
• Kumar Mehata A, Bharti S, Singh P, et al. Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy. Colloids Surf B Biointerfaces. 2019;173:366–377.
   PubMed Web of Science ®Google Scholar
• Gan H, Chen L, Sui X, et al. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma. Mater Sci Eng C Mater Biol Appl. 2018;91:395–403.
   PubMed Web of Science ®Google Scholar
• Calero R, Morchon E, Martinez-Argudo I, et al. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett. 2017;406:1–11.
   PubMed Web of Science ®Google Scholar
• Chen L, Jin T, Zhu K, et al. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor trichostatin a synergistically exert anti-tumor activity in breast cancer. Oncotarget. 2017;8:11937–11949.
   PubMedGoogle Scholar
• Duong HD, Shin Y, Rhee JI. Development of novel optical pH sensors based on coumarin 6 and nile blue a encapsulated in resin particles and specific support materials. Mater Sci Eng C Mater Biol Appl. 2020;107:110323.
   PubMed Web of Science ®Google Scholar
• Tang X, Lyu Y, Li A, et al. Therapeutic effect of sorafenib-loaded TPGS-b-PCL nanoparticles on liver cancer. J Biomed Nanotechnol. 2018;14(2):396–403.
   PubMed Web of Science ®Google Scholar
• Naidu PSR, Norret M, Dunlop SA, et al. Novel hydrophilic copolymer-based nanoparticle enhances the therapeutic efficiency of doxorubicin in cultured MCF-7 cells. ACS Omega. 2019;4(17):17083–17089.
   PubMed Web of Science ®Google Scholar
• Tang X, Zhou S, Tao X, et al. Targeted delivery of docetaxel via Pi-Pi stacking stabilized dendritic polymeric micelles for enhanced therapy of liver cancer. Mater Sci Eng C-Mater Biol Appl. 2017;75:1042–1048.
   PubMed Web of Science ®Google Scholar
• Hackett BA, Cherry S. Flavivirus internalization is regulated by a size-dependent endocytic pathway. Proc Natl Acad Sci U S A. 2018;115(16):4246–4251.
   PubMed Web of Science ®Google Scholar
• Ukon N, Zhao S, Yu W, et al. Dynamic PET evaluation of elevated FLT level after sorafenib treatment in mice bearing human renal cell carcinoma xenograft. EJNMMI Res. 2016;6(1):90.
   PubMed Web of Science ®Google Scholar
• Inuzuka H, Shaik S, Onoyama I, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471(7336):104–109.
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z, Zhao H, Dorota Halicka H, et al. Fluorochrome-labeled inhibitors of caspases: expedient in vitro and in vivo markers of apoptotic cells for rapid cytometric analysis. Methods Mol Biol. 2017;1644:61–73.
   PubMedGoogle Scholar
• Liu X, Xie C, Li A, et al. BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway. Am J Transl Res. 2019;11(12):7255–7271.
   PubMed Web of Science ®Google Scholar
• Akhtar MJ, Ahamed M, Alhadlaq HA, et al. Mitochondrial dysfunction, autophagy stimulation and non-apoptotic cell death caused by nitric oxide-inducing Pt-coated Au nanoparticle in human lung carcinoma cells. Biochim Biophys Acta Gen Subj. 2020;1864(1):129452.
   PubMed Web of Science ®Google Scholar
• Bidkhori G, Benfeitas R, Klevstig M, et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc Natl Acad Sci U S A. 2018;115(50):E11874–83.
   PubMed Web of Science ®Google Scholar
• Wani NA, Zhang B, Teng KY, et al. Reprograming of glucose metabolism by zerumbone suppresses hepatocarcinogenesis. Mol Cancer Res. 2018;16(2):256–268.
   PubMed Web of Science ®Google Scholar
• Huynh H, Ngo VC, Koong HN, et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol. 2010;52(1):79–87.
   PubMed Web of Science ®Google Scholar
• Toh TB, Lim JJ, Hooi L, et al. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma. J Hepatol. 2020;72(1):104–118.
   PubMed Web of Science ®Google Scholar
• Wang F, Bank T, Malnassy G, et al. Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. Hepatol Commun. 2018;2(6):732–746.
   PubMed Web of Science ®Google Scholar
• Gedaly R, Angulo P, Hundley J, et al. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res. 2010;30(12):4951–4958.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Pressiani T, Merle P. Systemic treatment options in hepatocellular carcinoma. Liver Cancer. 2019;8(6):427–446.
   PubMed Web of Science ®Google Scholar